TY - JOUR T1 - Study on the Validity of Pancreaticoduodenectomy in the Elderly JF - Anticancer Research JO - Anticancer Res SP - 5309 LP - 5316 VL - 37 IS - 9 AU - YASURO FUTAGAWA AU - MASARU KANEHIRA AU - KENEI FURUKAWA AU - HIROAKI KITAMURA AU - SEIYA YOSHIDA AU - TERUYUKI USUBA AU - TAKEYUKI MISAWA AU - YUICHI ISHIDA AU - TOMOYOSHI OKAMOTO AU - KATSUHIKO YANAGA Y1 - 2017/09/01 UR - http://ar.iiarjournals.org/content/37/9/5309.abstract N2 - Aim: Pancreaticoduodenectomy (PD) is still the only curative treatment for periampullary cancer. Confirming the outcomes of PD in elderly patients is important as the aging population continues to grow. Patients and Methods: We analyzed 340 patients with periampullary cancer who underwent PD, dividing them into three groups by age: group A: aged 64 years or younger, n=115; group B: 65-74 years, n=144; and group C: 75 years or older, n=81. Results: Group C had a significantly higher 60-day mortality of 6.3% (p=0.04), the lowest 5-year overall survival rate of 9.9% (p=0.02), and there was no impact of staging of the Union for International Cancer Control classification on overall survival of patients with pancreatic cancer. Independent prognostic factors of group C in the multivariate analysis were pancreatic cancer and reoperation. Conclusion: For elderly patients aged 75 years or over, caution should be exercised in selecting PD for patients with pancreatic cancer. ER -